Industries > Pharma > Tamiflu (Oseltamivir Phosphate) Market Report 2021-2031
Tamiflu (Oseltamivir Phosphate) Market Report 2021-2031
By Drug Type (Branded Drug, and Generic Drug), By Dosage Form (Capsule, and Suspension), By Indication (Influenza A, Influenza B, and Others), By Patient Demographics (Adults, Geriatric, and Pediatric), By End User (Hospital, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Leading Regional/ Country market analysis
Tamiflu (Oseltamivir Phosphate) Market– our new study reveals trends, R&D progress, and predicted revenues
Where the Tamiflu (Oseltamivir Phosphate) is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our 300+ page report provides 380+ tables and 360+ charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Tamiflu (Oseltamivir Phosphate) Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
• Revenue and growth forecasts from 2021 to 2031 for the Global Tamiflu (Oseltamivir Phosphate) Market By Drug Type
• Branded Drug
• Generic Drug
• Revenue and growth forecasts from 2021 to 2031 for the Global Tamiflu (Oseltamivir Phosphate) Market By Dosage Form
• Capsule
• Suspension
• Revenue and growth forecasts from 2021 to 2031 for the Global Tamiflu (Oseltamivir Phosphate) Market By Indication
• Influenza A
• Influenza B
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Tamiflu (Oseltamivir Phosphate) Market By Patient Demographics
• Adults
• Geriatric
• Pediatric
• Revenue and growth forecasts from 2021 to 2031 for the Global Tamiflu (Oseltamivir Phosphate) Market By End User
• Hospital
• Homecare
• Specialty Clinics
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Tamiflu (Oseltamivir Phosphate) Market By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Tamiflu (Oseltamivir Phosphate) Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Tamiflu (Oseltamivir Phosphate) Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Tamiflu (Oseltamivir Phosphate) Market report helps you
In summary, our 300+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Tamiflu (Oseltamivir Phosphate) Market, with forecasts for Get our report today Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031: By Drug Type, Dosage Form, Indication, Patient Demographics, By End User, Distribution Channel and Leading Regional/ Country market analysis each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Tamiflu (Oseltamivir Phosphate) market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Tamiflu (Oseltamivir Phosphate) Market. Some of the company’s profiled in this report include
• F.Hoffmann-La Roche Ltd.
• NATCO Pharma Limited
• Teva Pharmaceutical Industries Ltd.
• LUPIN Limited
• Amneal pharmaceuticals LLC
• Zydus Cadila
• Sun Pharmaceutical Industries Ltd.
• Alembic Pharmaceuticals Limited
• Mylan N.V.
• Hetero Group
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Tamiflu (Oseltamivir Phosphate) Market and leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Tamiflu (Oseltamivir Phosphate) Market Report 2021-2031: By Drug Type (Branded Drug, and Generic Drug), By Dosage Form (Capsule, and Suspension), By Indication (Influenza A, Influenza B, and Others), By Patient Demographics (Adults, Geriatric, and Pediatric), By End User (Hospital, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Leading Regional/ Country market analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Tamiflu (Oseltamivir Phosphate) Market
2.1. Tamiflu (Oseltamivir Phosphate) Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Tamiflu (Oseltamivir Phosphate) Market Overview
3.1. Global Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Region
3.2. Global Tamiflu (Oseltamivir Phosphate) Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing prevalence of influenza and flu
3.3.1.2. Rising investment in tamiflu (oseltamivir phosphate)
3.3.1.3. Increasing research and developments
3.3.1.4. Increasing awareness regarding influenza and flu treatment
3.3.2. Market Restraints
3.3.2.1. Stringent regulation associated with product development
3.3.2.2. High cost of development
3.3.2.3. Unmet medical needs
3.3.3. Opportunities
3.3.3.1. Increasing strategic initiatives in retinal disorders treatment drugs
3.3.3.2. Growing regulatory approvals
3.3.4. Challenges
3.3.4.1. Side effects associated with the drug
3.3.4.2. Availability of Alternative Methods
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast 2021-2031, By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Branded Drug
4.1.1.1. Branded Drug market size and forecast, 2021-2031 (USD Million)
4.1.2. Generic Drug
4.1.2.1. Generic Drug market size and forecast, 2021-2031 (USD Million)
5. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 By Dosage Form (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Capsule
5.1.1.1. Capsule market size and forecast, 2021-2031 (USD Million)
5.1.2. Suspension
5.1.2.1. Suspension market size and forecast, 2021-2031 (USD Million)
6. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Geriatric
6.1.1.1. Geriatric market size and forecast, 2021-2031 (USD Million)
6.1.2. Adult
6.1.2.1. Adult Market size and forecast, 2021-2031 (USD Million)
6.1.3. Pediatric
6.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
7. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 By Indication (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Influenza A
7.1.1.1. Influenza A market size and forecast, 2021-2031 (USD Million)
7.1.2. Influenza B
7.1.2.1. Influenza B market size and forecast, 2021-2031 (USD Million)
7.1.3. Others
7.1.3.1. Others market size and forecast, 2021-2031 (USD Million)
8. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Hospitals
8.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
8.1.2. Homecare
8.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
8.1.3. Specialty Clinics
8.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
8.1.4. Others
8.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
9. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospitals Pharmacy
9.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
9.1.2. Retail Pharmacy
9.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
9.1.3. Online Pharmacies
9.1.3.1. Online Pharmacies market size and forecast, 2021-2031 (USD Million)
10. North America Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. North America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Drug Type
10.2.1.1. XX Driving/Opportunity Factor
10.2.1.2. XX Driving/Opportunity Factor
10.3. North America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Dosage Form
10.3.1.1. XX Driving/Opportunity Factor
10.3.1.2. XX Driving/Opportunity Factor
10.4. North America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Indication
10.4.1.1. XX Driving/Opportunity Factor
10.4.1.2. XX Driving/Opportunity Factor
10.5. North America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Patient Demographics
10.5.1.1. XX Driving/Opportunity Factor
10.5.1.2. XX Driving/Opportunity Factor
10.6. North America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By End-User
10.6.1.1. XX Driving/Opportunity Factor
10.6.1.2. XX Driving/Opportunity Factor
10.7. North America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Distribution Channel
10.7.1.1. XX Driving/Opportunity Factor
10.7.1.2. XX Driving/Opportunity Factor
10.8. U.S. Tamiflu (Oseltamivir Phosphate) Market
10.8.1.1. XX Driving/Opportunity Factor
10.8.1.2. XX Driving/Opportunity Factor
10.9. Canada Tamiflu (Oseltamivir Phosphate) Market
10.9.1.1. XX Driving/Opportunity Factor
10.9.1.2. XX Driving/Opportunity Factor
11. Europe Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Europe Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Drug Type
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. Europe Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Dosage Form
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. Europe Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Patient Demographics
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. Europe Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Indication
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. Europe Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By End-User
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. Europe Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Distribution Channel
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. UK Tamiflu (Oseltamivir Phosphate) Market
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. Germany Tamiflu (Oseltamivir Phosphate) Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. France Tamiflu (Oseltamivir Phosphate) Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
11.11. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market
11.11.1.1. XX Driving/Opportunity Factor
11.11.1.2. XX Driving/Opportunity Factor
12. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Asia-Pacific Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Drug Type
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Asia-Pacific Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Dosage Form
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Asia-Pacific Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Patient Demographics
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Asia-Pacific Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Indication
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Asia-Pacific Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By End-User
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Asia-Pacific Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Distribution Channel
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. China Tamiflu (Oseltamivir Phosphate) Market
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. India Tamiflu (Oseltamivir Phosphate) Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Japan Tamiflu (Oseltamivir Phosphate) Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. Rest of Asia Pacific Tamiflu (Oseltamivir Phosphate) Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
13. Latin America Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Latin America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Drug Type
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Latin America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Dosage Form
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Latin America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Patient Demographics
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Latin America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Indication
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Latin America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By End-User
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Latin America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Distribution Channel
13.8. Brazil Tamiflu (Oseltamivir Phosphate) Market
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Mexico Tamiflu (Oseltamivir Phosphate) Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. Rest of Latin America Tamiflu (Oseltamivir Phosphate) Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
14. MEA Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. MEA Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Drug Type
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. MEA Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Dosage Form
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. MEA Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Patient Demographics
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. MEA Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Indication
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. MEA Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By End-User
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. MEA Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Distribution Channel
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. GCC Tamiflu (Oseltamivir Phosphate) Market
14.8.1.1. XX Driving/Opportunity Factor
14.8.1.2. XX Driving/Opportunity Factor
14.9. South Africa Tamiflu (Oseltamivir Phosphate) Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Rest of MEA Tamiflu (Oseltamivir Phosphate) Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
15. Companies in the Tamiflu (Oseltamivir Phosphate) Market
15.1. F.Hoffmann-La Roche Ltd.
15.1.1. Company Snapshot
15.1.2. Company Overview
15.1.3. Financial Performance (2015-2019)
15.1.3.1. Net Revenue
15.1.3.2. Gross Profit
15.1.3.3. Geographical Revenue, 2019
15.1.4. Product Offerings
15.1.5. Recent Initiatives (2017-2019)
15.2. NATCO Pharma Limited
15.2.1. Company Snapshot
15.2.2. Company Overview
15.2.3. Financial Performance (2015-2019)
15.2.3.1. Net Revenue
15.2.3.2. Gross Profit
15.2.3.3. Geographical Revenue, 2019
15.2.4. Product Offerings
15.2.5. Recent Initiatives (2017-2019)
15.3. Teva Pharmaceutical Industries Ltd.
15.3.1. Company Snapshot
15.3.2. Company Overview
15.3.3. Financial Performance (2015-2019)
15.3.3.1. Net Revenue
15.3.3.2. Gross Profit
15.3.3.3. Geographical Revenue, 2019
15.3.4. Product Offerings
15.3.5. Recent Initiatives (2017-2019)
15.4. LUPIN Limited
15.4.1. Company Snapshot
15.4.2. Company Overview
15.4.3. Financial Performance (2015-2019)
15.4.3.1. Net Revenue
15.4.3.2. Gross Profit
15.4.3.3. Geographical Revenue, 2019
15.4.4. Product Offerings
15.4.5. Recent Initiatives (2017-2019)
15.5. AMNEAL PHARMACEUTICALS LLC
15.5.1. Company Snapshot
15.5.2. Company Overview
15.5.3. Financial Performance (2015-2019)
15.5.3.1. Net Revenue
15.5.3.2. Gross Profit
15.5.3.3. Geographical Revenue, 2019
15.5.4. Product Offerings
15.5.5. Recent Initiatives (2017-2019)
15.6. Zydus Cadila
15.6.1. Company Snapshot
15.6.2. Company Overview
15.6.3. Financial Performance (2015-2019)
15.6.3.1. Net Revenue
15.6.3.2. Gross Profit
15.6.3.3. Geographical Revenue, 2019
15.6.4. Product Offerings
15.6.5. Recent Initiatives (2017-2019)
15.7. Alembic Pharmaceuticals Limited
15.7.1. Company Snapshot
15.7.2. Company Overview
15.7.3. Financial Performance (2015-2019)
15.7.3.1. Net Revenue
15.7.3.2. Gross Profit
15.7.3.3. Geographical Revenue, 2019
15.7.4. Product Offerings
15.7.5. Recent Initiatives (2017-2019)
15.8. Mylan N.V.
15.8.1. Company Snapshot
15.8.2. Company Overview
15.8.3. Financial Performance (2015-2019)
15.8.3.1. Net Revenue
15.8.3.2. Gross Profit
15.8.3.3. Geographical Revenue, 2019
15.8.4. Product Offerings
15.8.5. Recent Initiatives (2017-2019)
15.9. Novartis AG
15.9.1. Company Snapshot
15.9.2. Company Overview
15.9.3. Financial Performance (2015-2019)
15.9.3.1. Net Revenue
15.9.3.2. Gross Profit
15.9.3.3. Geographical Revenue, 2019
15.9.4. Product Offerings
15.9.5. Recent Initiatives (2017-2019)
15.10. Hetero Group
15.10.1. Company Snapshot
15.10.2. Company Overview
15.10.3. Financial Performance (2015-2019)
15.10.3.1. Net Revenue
15.10.3.2. Gross Profit
15.10.3.3. Geographical Revenue, 2019
15.10.4. Product Offerings
15.10.5. Recent Initiatives (2017-2019)
15.11. Other Notable Players
16. Conclusion
17. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Tamiflu (Oseltamivir Phosphate) Market Drivers & Restraints 2021
Table 7. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 168. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 198. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 199. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 222. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 242. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 243. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 244. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 245. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 246. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 247. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 248. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 249. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 250. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 251. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 252. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 253. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 254. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 255. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 256. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 257. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 258. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 259. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 260. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 261. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 262. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. Leading 10 Tamiflu (Oseltamivir Phosphate) Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 367. F.Hoffmann-La Roche Ltd.Profile 2019 (CEO, HQ, Founded, Website)
Table 368. F.Hoffmann-La Roche Ltd. Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 369. NATCO Pharma Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 370. NATCO Pharma Limited Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 371. Teva Pharmaceutical Industries Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 372. Teva Pharmaceutical Industries Ltd..Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 373. LUPIN Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 374. LUPIN Limited Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 375. AMNEAL PHARMACEUTICALS LLC Profile 2019 (CEO, HQ, Founded, Website)
Table 376. AMNEAL PHARMACEUTICALS LLC Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 377. Zydus Cadila Profile 2019 (CEO, HQ, Founded, Website)
Table 378. Zydus Cadila Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 379. Alembic Pharmaceuticals Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 380. Alembic Pharmaceuticals Limited Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 381. Mylan N.V. Profile 2019 (CEO, HQ, Founded, Website)
Table 382. Mylan N.V. Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 383. Novartis AG Profile 2019 (CEO, HQ, Founded, Website)
Table 384. Novartis AG Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 385. Hetero Group Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 386. Hetero Group Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 387. Other Companies Involved in the Tamiflu (Oseltamivir Phosphate) Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Tamiflu (Oseltamivir Phosphate) Market Drivers & Restraints 2021
Figure 7. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 123. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 128. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 133. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 138. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 143. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 148. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 153. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 158. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 163. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 168. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 173. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 183. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 188. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 198. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 199. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 200. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 201. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 202. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 203. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 204. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 205. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 206. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 207. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 208. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 209. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 210. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 211. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 212. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 213. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 214. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 215. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 216. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 217. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 218. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 219. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 220. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 221. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 222. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 223. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 224. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 225. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 226. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 227. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 228. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 229. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 230. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 231. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 232. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 233. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 234. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 235. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 236. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 237. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 238. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 239. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 240. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 241. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 242. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 243. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 244. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 245. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 246. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 247. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 248. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 249. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 250. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 251. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 252. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 253. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 254. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 255. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 256. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 257. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 258. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 259. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 260. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 261. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 262. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. Porter’s Five Force Analysis
Companies Mentioned
1. Eisai Co Ltd
2. Novo Nordisk A/S
3. Alexion Pharmaceuticals Inc
4. Takeda Pharmaceutical Co Ltd
5. Chugai Pharmaceutical Co Ltd
6. Perrigo Company PLC
7. Astellas Pharma Inc
8. Mitsubishi Tanabe Pharma Corp
9. GlaxoSmithKline PLC
10. Biomarin Pharmaceutical Inc
11. Grifols SA
12. UCB SA
13. Johnson & Johnson
14. Shanghai Fosun Pharmaceutical Group Co Ltd
15. Jiangsu Hengrui Medicine Co Ltd
16. Allergan plc
17. Shire PLC
18. Kyowa Hakko Kirin Co Ltd
19. Pfizer Inc
20. Taisho Pharmaceutical Holdings Co Ltd
21. MYL.O
22. Zoetis Inc
23. Bristol-Myers Squibb Co
24. Merck & Co Inc
25. AbbVie Inc
26. Jazz Pharmaceuticals PLC
27. Sumitomo Dainippon Pharma Co Ltd
28. AstraZeneca PLC
29. China Grand Automotive Services Co Ltd
30. Daiichi Sankyo Co Ltd
31. Novartis AG
32. Tasly Pharmaceutical Group Co Ltd
33. CSL Ltd
34. Biogen Inc
35. Orion Oyj
36. Bayer AG
37. CSPC Pharmaceutical Group Ltd
38. Sanofi SA
39. Roche Holding AG
40. Ono Pharmaceutical Co Ltd
41. Beijing Tongrentang Co Ltd
42. Kangmei Pharmaceutical Co Ltd
43. Ipsen SA
44. Abbott Laboratories
45. Shionogi & Co Ltd
46. Eli Lilly and Co
47. Recordati Industria Chimica e Farmaceutica SpA
48. Hikma Pharmaceuticals PLC
49. Teva Pharmaceutical Industries Ltd
50. Merck KGaA
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Tamiflu (Oseltamivir Phosphate) Market
2.1. Tamiflu (Oseltamivir Phosphate) Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Tamiflu (Oseltamivir Phosphate) Market Overview
3.1. Global Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Region
3.2. Global Tamiflu (Oseltamivir Phosphate) Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing prevalence of influenza and flu
3.3.1.2. Rising investment in tamiflu (oseltamivir phosphate)
3.3.1.3. Increasing research and developments
3.3.1.4. Increasing awareness regarding influenza and flu treatment
3.3.2. Market Restraints
3.3.2.1. Stringent regulation associated with product development
3.3.2.2. High cost of development
3.3.2.3. Unmet medical needs
3.3.3. Opportunities
3.3.3.1. Increasing strategic initiatives in retinal disorders treatment drugs
3.3.3.2. Growing regulatory approvals
3.3.4. Challenges
3.3.4.1. Side effects associated with the drug
3.3.4.2. Availability of Alternative Methods
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast 2021-2031, By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Branded Drug
4.1.1.1. Branded Drug market size and forecast, 2021-2031 (USD Million)
4.1.2. Generic Drug
4.1.2.1. Generic Drug market size and forecast, 2021-2031 (USD Million)
5. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 By Dosage Form (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Capsule
5.1.1.1. Capsule market size and forecast, 2021-2031 (USD Million)
5.1.2. Suspension
5.1.2.1. Suspension market size and forecast, 2021-2031 (USD Million)
6. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Geriatric
6.1.1.1. Geriatric market size and forecast, 2021-2031 (USD Million)
6.1.2. Adult
6.1.2.1. Adult Market size and forecast, 2021-2031 (USD Million)
6.1.3. Pediatric
6.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
7. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 By Indication (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Influenza A
7.1.1.1. Influenza A market size and forecast, 2021-2031 (USD Million)
7.1.2. Influenza B
7.1.2.1. Influenza B market size and forecast, 2021-2031 (USD Million)
7.1.3. Others
7.1.3.1. Others market size and forecast, 2021-2031 (USD Million)
8. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Hospitals
8.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
8.1.2. Homecare
8.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
8.1.3. Specialty Clinics
8.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
8.1.4. Others
8.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
9. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospitals Pharmacy
9.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
9.1.2. Retail Pharmacy
9.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
9.1.3. Online Pharmacies
9.1.3.1. Online Pharmacies market size and forecast, 2021-2031 (USD Million)
10. North America Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. North America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Drug Type
10.2.1.1. XX Driving/Opportunity Factor
10.2.1.2. XX Driving/Opportunity Factor
10.3. North America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Dosage Form
10.3.1.1. XX Driving/Opportunity Factor
10.3.1.2. XX Driving/Opportunity Factor
10.4. North America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Indication
10.4.1.1. XX Driving/Opportunity Factor
10.4.1.2. XX Driving/Opportunity Factor
10.5. North America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Patient Demographics
10.5.1.1. XX Driving/Opportunity Factor
10.5.1.2. XX Driving/Opportunity Factor
10.6. North America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By End-User
10.6.1.1. XX Driving/Opportunity Factor
10.6.1.2. XX Driving/Opportunity Factor
10.7. North America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Distribution Channel
10.7.1.1. XX Driving/Opportunity Factor
10.7.1.2. XX Driving/Opportunity Factor
10.8. U.S. Tamiflu (Oseltamivir Phosphate) Market
10.8.1.1. XX Driving/Opportunity Factor
10.8.1.2. XX Driving/Opportunity Factor
10.9. Canada Tamiflu (Oseltamivir Phosphate) Market
10.9.1.1. XX Driving/Opportunity Factor
10.9.1.2. XX Driving/Opportunity Factor
11. Europe Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Europe Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Drug Type
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. Europe Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Dosage Form
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. Europe Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Patient Demographics
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. Europe Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Indication
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. Europe Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By End-User
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. Europe Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Distribution Channel
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. UK Tamiflu (Oseltamivir Phosphate) Market
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. Germany Tamiflu (Oseltamivir Phosphate) Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. France Tamiflu (Oseltamivir Phosphate) Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
11.11. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market
11.11.1.1. XX Driving/Opportunity Factor
11.11.1.2. XX Driving/Opportunity Factor
12. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Asia-Pacific Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Drug Type
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Asia-Pacific Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Dosage Form
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Asia-Pacific Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Patient Demographics
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Asia-Pacific Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Indication
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Asia-Pacific Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By End-User
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Asia-Pacific Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Distribution Channel
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. China Tamiflu (Oseltamivir Phosphate) Market
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. India Tamiflu (Oseltamivir Phosphate) Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Japan Tamiflu (Oseltamivir Phosphate) Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. Rest of Asia Pacific Tamiflu (Oseltamivir Phosphate) Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
13. Latin America Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Latin America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Drug Type
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Latin America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Dosage Form
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Latin America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Patient Demographics
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Latin America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Indication
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Latin America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By End-User
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Latin America Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Distribution Channel
13.8. Brazil Tamiflu (Oseltamivir Phosphate) Market
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Mexico Tamiflu (Oseltamivir Phosphate) Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. Rest of Latin America Tamiflu (Oseltamivir Phosphate) Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
14. MEA Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. MEA Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Drug Type
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. MEA Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Dosage Form
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. MEA Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Patient Demographics
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. MEA Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Indication
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. MEA Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By End-User
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. MEA Tamiflu (Oseltamivir Phosphate) Market Size and Forecast By Distribution Channel
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. GCC Tamiflu (Oseltamivir Phosphate) Market
14.8.1.1. XX Driving/Opportunity Factor
14.8.1.2. XX Driving/Opportunity Factor
14.9. South Africa Tamiflu (Oseltamivir Phosphate) Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Rest of MEA Tamiflu (Oseltamivir Phosphate) Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
15. Companies in the Tamiflu (Oseltamivir Phosphate) Market
15.1. F.Hoffmann-La Roche Ltd.
15.1.1. Company Snapshot
15.1.2. Company Overview
15.1.3. Financial Performance (2015-2019)
15.1.3.1. Net Revenue
15.1.3.2. Gross Profit
15.1.3.3. Geographical Revenue, 2019
15.1.4. Product Offerings
15.1.5. Recent Initiatives (2017-2019)
15.2. NATCO Pharma Limited
15.2.1. Company Snapshot
15.2.2. Company Overview
15.2.3. Financial Performance (2015-2019)
15.2.3.1. Net Revenue
15.2.3.2. Gross Profit
15.2.3.3. Geographical Revenue, 2019
15.2.4. Product Offerings
15.2.5. Recent Initiatives (2017-2019)
15.3. Teva Pharmaceutical Industries Ltd.
15.3.1. Company Snapshot
15.3.2. Company Overview
15.3.3. Financial Performance (2015-2019)
15.3.3.1. Net Revenue
15.3.3.2. Gross Profit
15.3.3.3. Geographical Revenue, 2019
15.3.4. Product Offerings
15.3.5. Recent Initiatives (2017-2019)
15.4. LUPIN Limited
15.4.1. Company Snapshot
15.4.2. Company Overview
15.4.3. Financial Performance (2015-2019)
15.4.3.1. Net Revenue
15.4.3.2. Gross Profit
15.4.3.3. Geographical Revenue, 2019
15.4.4. Product Offerings
15.4.5. Recent Initiatives (2017-2019)
15.5. AMNEAL PHARMACEUTICALS LLC
15.5.1. Company Snapshot
15.5.2. Company Overview
15.5.3. Financial Performance (2015-2019)
15.5.3.1. Net Revenue
15.5.3.2. Gross Profit
15.5.3.3. Geographical Revenue, 2019
15.5.4. Product Offerings
15.5.5. Recent Initiatives (2017-2019)
15.6. Zydus Cadila
15.6.1. Company Snapshot
15.6.2. Company Overview
15.6.3. Financial Performance (2015-2019)
15.6.3.1. Net Revenue
15.6.3.2. Gross Profit
15.6.3.3. Geographical Revenue, 2019
15.6.4. Product Offerings
15.6.5. Recent Initiatives (2017-2019)
15.7. Alembic Pharmaceuticals Limited
15.7.1. Company Snapshot
15.7.2. Company Overview
15.7.3. Financial Performance (2015-2019)
15.7.3.1. Net Revenue
15.7.3.2. Gross Profit
15.7.3.3. Geographical Revenue, 2019
15.7.4. Product Offerings
15.7.5. Recent Initiatives (2017-2019)
15.8. Mylan N.V.
15.8.1. Company Snapshot
15.8.2. Company Overview
15.8.3. Financial Performance (2015-2019)
15.8.3.1. Net Revenue
15.8.3.2. Gross Profit
15.8.3.3. Geographical Revenue, 2019
15.8.4. Product Offerings
15.8.5. Recent Initiatives (2017-2019)
15.9. Novartis AG
15.9.1. Company Snapshot
15.9.2. Company Overview
15.9.3. Financial Performance (2015-2019)
15.9.3.1. Net Revenue
15.9.3.2. Gross Profit
15.9.3.3. Geographical Revenue, 2019
15.9.4. Product Offerings
15.9.5. Recent Initiatives (2017-2019)
15.10. Hetero Group
15.10.1. Company Snapshot
15.10.2. Company Overview
15.10.3. Financial Performance (2015-2019)
15.10.3.1. Net Revenue
15.10.3.2. Gross Profit
15.10.3.3. Geographical Revenue, 2019
15.10.4. Product Offerings
15.10.5. Recent Initiatives (2017-2019)
15.11. Other Notable Players
16. Conclusion
17. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Tamiflu (Oseltamivir Phosphate) Market Drivers & Restraints 2021
Table 7. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 168. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 198. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 199. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 222. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 242. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 243. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 244. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 245. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 246. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 247. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 248. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 249. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 250. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 251. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 252. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 253. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 254. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 255. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 256. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 257. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 258. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 259. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 260. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 261. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 262. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. Leading 10 Tamiflu (Oseltamivir Phosphate) Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 367. F.Hoffmann-La Roche Ltd.Profile 2019 (CEO, HQ, Founded, Website)
Table 368. F.Hoffmann-La Roche Ltd. Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 369. NATCO Pharma Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 370. NATCO Pharma Limited Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 371. Teva Pharmaceutical Industries Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 372. Teva Pharmaceutical Industries Ltd..Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 373. LUPIN Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 374. LUPIN Limited Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 375. AMNEAL PHARMACEUTICALS LLC Profile 2019 (CEO, HQ, Founded, Website)
Table 376. AMNEAL PHARMACEUTICALS LLC Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 377. Zydus Cadila Profile 2019 (CEO, HQ, Founded, Website)
Table 378. Zydus Cadila Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 379. Alembic Pharmaceuticals Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 380. Alembic Pharmaceuticals Limited Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 381. Mylan N.V. Profile 2019 (CEO, HQ, Founded, Website)
Table 382. Mylan N.V. Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 383. Novartis AG Profile 2019 (CEO, HQ, Founded, Website)
Table 384. Novartis AG Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 385. Hetero Group Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 386. Hetero Group Tamiflu (Oseltamivir Phosphate) Product Offering (Segment, Product Offerings)
Table 387. Other Companies Involved in the Tamiflu (Oseltamivir Phosphate) Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Tamiflu (Oseltamivir Phosphate) Market Drivers & Restraints 2021
Figure 7. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Branded Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Generic Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Capsule Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Suspension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Influenza A Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Influenza B Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 123. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 128. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 133. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 138. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 143. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 148. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 153. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. North America Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 158. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. US Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 163. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Canada Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 168. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 173. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 183. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 188. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 198. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 199. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 200. Europe Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 201. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 202. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 203. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 204. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 205. UK Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 206. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 207. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 208. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 209. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 210. Germany Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 211. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 212. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 213. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 214. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 215. France Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 216. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 217. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 218. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 219. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 220. Rest of Europe Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 221. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 222. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 223. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 224. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 225. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 226. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 227. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 228. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 229. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 230. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 231. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 232. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 233. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 234. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 235. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 236. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 237. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 238. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 239. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 240. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 241. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 242. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 243. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 244. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 245. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 246. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 247. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 248. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 249. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 250. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 251. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 252. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 253. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 254. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 255. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 256. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 257. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 258. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 259. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 260. China Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 261. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 262. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. India Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. Japan Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. RoAPAC Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Middle East Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. Latin America Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. Africa Tamiflu (Oseltamivir Phosphate) Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. Porter’s Five Force Analysis
Companies Mentioned
1. Eisai Co Ltd
2. Novo Nordisk A/S
3. Alexion Pharmaceuticals Inc
4. Takeda Pharmaceutical Co Ltd
5. Chugai Pharmaceutical Co Ltd
6. Perrigo Company PLC
7. Astellas Pharma Inc
8. Mitsubishi Tanabe Pharma Corp
9. GlaxoSmithKline PLC
10. Biomarin Pharmaceutical Inc
11. Grifols SA
12. UCB SA
13. Johnson & Johnson
14. Shanghai Fosun Pharmaceutical Group Co Ltd
15. Jiangsu Hengrui Medicine Co Ltd
16. Allergan plc
17. Shire PLC
18. Kyowa Hakko Kirin Co Ltd
19. Pfizer Inc
20. Taisho Pharmaceutical Holdings Co Ltd
21. MYL.O
22. Zoetis Inc
23. Bristol-Myers Squibb Co
24. Merck & Co Inc
25. AbbVie Inc
26. Jazz Pharmaceuticals PLC
27. Sumitomo Dainippon Pharma Co Ltd
28. AstraZeneca PLC
29. China Grand Automotive Services Co Ltd
30. Daiichi Sankyo Co Ltd
31. Novartis AG
32. Tasly Pharmaceutical Group Co Ltd
33. CSL Ltd
34. Biogen Inc
35. Orion Oyj
36. Bayer AG
37. CSPC Pharmaceutical Group Ltd
38. Sanofi SA
39. Roche Holding AG
40. Ono Pharmaceutical Co Ltd
41. Beijing Tongrentang Co Ltd
42. Kangmei Pharmaceutical Co Ltd
43. Ipsen SA
44. Abbott Laboratories
45. Shionogi & Co Ltd
46. Eli Lilly and Co
47. Recordati Industria Chimica e Farmaceutica SpA
48. Hikma Pharmaceuticals PLC
49. Teva Pharmaceutical Industries Ltd
50. Merck KGaA
Companies Profiled in the Report
1. F.Hoffmann-La Roche Ltd.
2. NATCO Pharma Limited
3. Teva Pharmaceutical Industries Ltd.
4. LUPIN Limited
5. Amneal pharmaceuticals LLC
6. Zydus Cadila
7. Sun Pharmaceutical Industries Ltd.
8. Alembic Pharmaceuticals Limited
9. Mylan N.V.
10. Hetero Group
List of Companies Mentioned in the Report:
1. Eisai Co Ltd
2. Novo Nordisk A/S
3. Alexion Pharmaceuticals Inc
4. Takeda Pharmaceutical Co Ltd
5. Chugai Pharmaceutical Co Ltd
6. Perrigo Company PLC
7. Astellas Pharma Inc
8. Mitsubishi Tanabe Pharma Corp
9. GlaxoSmithKline PLC
10. Biomarin Pharmaceutical Inc
11. Grifols SA
12. UCB SA
13. Johnson & Johnson
14. Shanghai Fosun Pharmaceutical Group Co Ltd
15. Jiangsu Hengrui Medicine Co Ltd
16. Allergan plc
17. Shire PLC
18. Kyowa Hakko Kirin Co Ltd
19. Pfizer Inc
20. Taisho Pharmaceutical Holdings Co Ltd
21. MYL.O
22. Zoetis Inc
23. Bristol-Myers Squibb Co
24. Merck & Co Inc
25. AbbVie Inc
26. Jazz Pharmaceuticals PLC
27. Sumitomo Dainippon Pharma Co Ltd
28. AstraZeneca PLC
29. China Grand Automotive Services Co Ltd
30. Daiichi Sankyo Co Ltd
31. Novartis AG
32. Tasly Pharmaceutical Group Co Ltd
33. CSL Ltd
34. Biogen Inc
35. Orion Oyj
36. Bayer AG
37. CSPC Pharmaceutical Group Ltd
38. Sanofi SA
39. Roche Holding AG
40. Ono Pharmaceutical Co Ltd
41. Beijing Tongrentang Co Ltd
42. Kangmei Pharmaceutical Co Ltd
43. Ipsen SA
44. Abbott Laboratories
45. Shionogi & Co Ltd
46. Eli Lilly and Co
47. Recordati Industria Chimica e Farmaceutica SpA
48. Hikma Pharmaceuticals PLC
49. Teva Pharmaceutical Industries Ltd
50. Merck KGaA
List of Organizations Mentioned in the Report:
1. Centre for Pharmaceutical Administration Health Sciences Authority
2. Central Drug Standard Control Organization (CDSCO)
3. Organisation for Economic Co-operation and Development (OECD)
4. European Medicines Agency (EMA)
5. Food and Drug Administration (FDA)
6. National Institutes of Health (NIH)
7. United Nations (UN)
8. United Nations Office on Drugs and Crime (UNODC)
9. United Nations Statistics Division (UNSD)
10. Statistical Office of the European Union (EUROSTAT)
11. University of Connecticut
12. World Health Organization (WHO)
13. The National Medical Products Administration (NMPA)
14. Indian Council of Medical Research (ICMR)
15. The Therapeutic Goods Administration
16. The Federal Institute for Drugs and Medical Devices (BfArM)
17. Pharmaceuticals and Medical Devices Agency (PMDA)
18. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
19. Ministry of Health, Labour & Welfare(MHLW)
20. Medicines and Healthcare Products Regulatory Agency (MHRA)
1. F.Hoffmann-La Roche Ltd.
2. NATCO Pharma Limited
3. Teva Pharmaceutical Industries Ltd.
4. LUPIN Limited
5. Amneal pharmaceuticals LLC
6. Zydus Cadila
7. Sun Pharmaceutical Industries Ltd.
8. Alembic Pharmaceuticals Limited
9. Mylan N.V.
10. Hetero Group
List of Companies Mentioned in the Report:
1. Eisai Co Ltd
2. Novo Nordisk A/S
3. Alexion Pharmaceuticals Inc
4. Takeda Pharmaceutical Co Ltd
5. Chugai Pharmaceutical Co Ltd
6. Perrigo Company PLC
7. Astellas Pharma Inc
8. Mitsubishi Tanabe Pharma Corp
9. GlaxoSmithKline PLC
10. Biomarin Pharmaceutical Inc
11. Grifols SA
12. UCB SA
13. Johnson & Johnson
14. Shanghai Fosun Pharmaceutical Group Co Ltd
15. Jiangsu Hengrui Medicine Co Ltd
16. Allergan plc
17. Shire PLC
18. Kyowa Hakko Kirin Co Ltd
19. Pfizer Inc
20. Taisho Pharmaceutical Holdings Co Ltd
21. MYL.O
22. Zoetis Inc
23. Bristol-Myers Squibb Co
24. Merck & Co Inc
25. AbbVie Inc
26. Jazz Pharmaceuticals PLC
27. Sumitomo Dainippon Pharma Co Ltd
28. AstraZeneca PLC
29. China Grand Automotive Services Co Ltd
30. Daiichi Sankyo Co Ltd
31. Novartis AG
32. Tasly Pharmaceutical Group Co Ltd
33. CSL Ltd
34. Biogen Inc
35. Orion Oyj
36. Bayer AG
37. CSPC Pharmaceutical Group Ltd
38. Sanofi SA
39. Roche Holding AG
40. Ono Pharmaceutical Co Ltd
41. Beijing Tongrentang Co Ltd
42. Kangmei Pharmaceutical Co Ltd
43. Ipsen SA
44. Abbott Laboratories
45. Shionogi & Co Ltd
46. Eli Lilly and Co
47. Recordati Industria Chimica e Farmaceutica SpA
48. Hikma Pharmaceuticals PLC
49. Teva Pharmaceutical Industries Ltd
50. Merck KGaA
List of Organizations Mentioned in the Report:
1. Centre for Pharmaceutical Administration Health Sciences Authority
2. Central Drug Standard Control Organization (CDSCO)
3. Organisation for Economic Co-operation and Development (OECD)
4. European Medicines Agency (EMA)
5. Food and Drug Administration (FDA)
6. National Institutes of Health (NIH)
7. United Nations (UN)
8. United Nations Office on Drugs and Crime (UNODC)
9. United Nations Statistics Division (UNSD)
10. Statistical Office of the European Union (EUROSTAT)
11. University of Connecticut
12. World Health Organization (WHO)
13. The National Medical Products Administration (NMPA)
14. Indian Council of Medical Research (ICMR)
15. The Therapeutic Goods Administration
16. The Federal Institute for Drugs and Medical Devices (BfArM)
17. Pharmaceuticals and Medical Devices Agency (PMDA)
18. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
19. Ministry of Health, Labour & Welfare(MHLW)
20. Medicines and Healthcare Products Regulatory Agency (MHRA)
Download sample pages
Complete the form below to download your free sample pages for Tamiflu (Oseltamivir Phosphate) Market Report 2021-2031Download sample pages
Complete the form below to download your free sample pages for Tamiflu (Oseltamivir Phosphate) Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033
The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033
31 May 2023
Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
26 May 2023
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033
The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033
24 May 2023
Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033
The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033
23 May 2023
